Neuronascent, Inc.

Years of testing ineffective neuroprotective agents to cure chronic neurodegenerative disease, it is time to test NNI's non-invasive neuroregenerative agent.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Clarksville, MD, US
  • Currency USD
  • Founded December 2004
  • Employees 2
  • Incorporation Type C-corp
  • Website neuronascent.com

Company Summary

Neuronascent discovers and develops neuron regenerative therapies. Our patented therapeutic promotes new neurons that correlate with a reversal in cognitive impairment, aimed at being the first, non-invasive therapy to promote new neurons and memory reversal in Alzheimer's disease (AD). The National Institute on Aging has completed all GLP safety studies for NNI-362. The aim is to submit an IND application to the FDA for lead candidate in 2016.

Team

Advisors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free